A detailed history of Blue Sky Capital Consultants Group, Inc. transactions in Moderna, Inc. stock. As of the latest transaction made, Blue Sky Capital Consultants Group, Inc. holds 15,119 shares of MRNA stock, worth $405,189. This represents 0.28% of its overall portfolio holdings.

Number of Shares
15,119
Previous 14,563 3.82%
Holding current value
$405,189
Previous $606 Million 29.22%
% of portfolio
0.28%
Previous 0.36%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025

BUY
$28.35 - $47.53 $15,762 - $26,426
556 Added 3.82%
15,119 $429 Million
Q4 2024

Feb 19, 2025

BUY
$36.85 - $63.93 $536,646 - $931,012
14,563 New
14,563 $606 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $10.5B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Blue Sky Capital Consultants Group, Inc. Portfolio

Follow Blue Sky Capital Consultants Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Sky Capital Consultants Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Blue Sky Capital Consultants Group, Inc. with notifications on news.